Research Topics
| R LindsaySummaryAffiliation: Helen Hayes Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadetsJamie A Ruffing
Clinical Research and Regional Bone Centers, Helen Hayes Hospital, West Haverstraw, NY, USA
Nutr Metab (Lond) 4:17. 2007..To determine the influence of menstrual irregularity, oral contraceptive use and other factors on bone mineral density (BMD) and bone size at different skeletal sites in 135 college-aged fit women...
Modeling the benefits of pamidronate in children with osteogenesis imperfectaRobert Lindsay
Department of Medicine, Columbia University, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Clin Invest 110:1239-41. 2002
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal womenRobert Lindsay
Internal Medicine, Helen Hayes Hospital, Rte 9W, West Haverstraw, NY 10993, USA
JAMA 287:2668-76. 2002..This lower-dose therapy's protection against loss of bone mineral density (BMD) associated with menopause has not been thoroughly investigated...
Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal womenRobert Lindsay
Helen Hayes Hospital, Route 9 W, West Haverstraw, NY 10993, USA
Osteoporos Int 16:372-9. 2005..In summary, continued bone loss among early postmenopausal women treated with lower doses of CE or CE/MPA is uncommon...
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human iliumRobert Lindsay
Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
J Bone Miner Res 22:495-502. 2007..Enhanced bone formation was associated with an increase in osteoblast apoptosis...
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosisRobert Lindsay
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
Arch Intern Med 164:2024-30. 2004..Teriparatide (recombinant human parathyroid hormone [1-34]) reduces fracture risk in postmenopausal women with osteoporosis. We assessed the safety and incidence of new vertebral fractures after withdrawal of teriparatide...
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatideRobert Lindsay
Clinical Research Center, New York State Department of Health, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Bone Miner Res 21:366-73. 2006..We show that 1 month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation...
Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosisRobert Lindsay
Helen Hayes Hospital, Route 9 W, West Haverstraw, NY 10993, USA
Osteoporos Int 16:306-12. 2005..To determine the longitudinal progression of fractures through a population of osteoporotic women with no existing vertebral fractures...
Hormones and bone health in postmenopausal womenRobert Lindsay
Helen Hayes Hospital, West Haverstraw, NY, USA
Endocrine 24:223-30. 2004..The other outcomes in WHI make it important to define appropriate clinical guidelines for use of hormone therapy for prevention of fractures in postmenopausal women...
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal womenRobert Lindsay
Department of Medicine, Helen Hayes Hospital, West Haverstraw, New York, New York, and Columbia University, New York, New York, USA
Fertil Steril 92:1045-52. 2009..To evaluate the efficacy of the tissue-selective estrogen complex, bazedoxifene/conjugated estrogens (BZA/CE), for postmenopausal osteoporosis prevention...
Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE)R Lindsay
Clinical Research Center, Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA
Osteoporos Int 22:447-51. 2011....
Risk of new vertebral fracture in the year following a fractureR Lindsay
Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA
JAMA 285:320-3. 2001..Vertebral fractures significantly increase lifetime risk of future fractures, but risk of further vertebral fractures in the period immediately following a vertebral fracture has not been evaluated...
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawalF Cosman
Clinical Research Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw 10993, USA
J Bone Miner Res 16:925-31. 2001..Furthermore, PTH in combination with hormone therapy is an effective means of increasing bone mass throughout the skeleton and specifically reducing vertebral fracture occurrence by 75-100%, compared with HRT alone...
Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient ratH Zhou
Helen Hayes Hospital, New York State Health Department, West Haverstraw 10993-1195, USA
J Bone Miner Res 16:1300-7. 2001..We conclude that continuous administration of PTH and estrogen increases cortical porosity but has substantial beneficial effects on vertebral cancellous bone volume and cortical width in OVX rats...
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy studyD W Dempster
Regional Bone Center, Helen Hayes Hospital. New York State Department of Health, West Haverstraw 10993, USA
J Bone Miner Res 16:1846-53. 2001..The results provide a structural basis for the recent demonstration that PTH treatment reduces the incidence of osteoporosis-related fractures...
Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 miceA Iida-Klein
Regional Bone, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Endocrinol 186:549-57. 2005..Short-term infusion of hPTH1-34 appears to be a good model to study the mechanisms underlying the catabolic action of PTH in mice...
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markersE S Kurland
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Clin Endocrinol Metab 85:3069-76. 2000....
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidismD W Dempster
Regional Bone Center, New York State Department of Health, Helen Hayes Hospital, West Haverstraw 10993, USA
J Clin Endocrinol Metab 84:1562-6. 1999....
Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in miceAkiko Iida-Klein
Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw 10993-1195, USA
J Bone Miner Res 17:808-16. 2002..In conclusion, PTH exerts an anabolic action at the tissue and cellular levels in intact mice and the magnitude and temporal pattern of this anabolic action, as assessed by densitometry and histomorphometry, are skeletal site specific...
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapyF Cosman
Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
Osteoporos Int 19:529-35. 2008..6%, hip BMD increased 1.2-3.6% and radius BMD declined 4.3%. During the follow-up year, on continued raloxifene, BMD declined slightly at all sites except the femoral neck...
Bone loss after cardiac transplantationRobert Lindsay
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA
N Engl J Med 350:751-4. 2004
Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysisJ W Nieves
Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
Am J Clin Nutr 67:18-24. 1998..2%/y with calcitonin alone. These results suggest that a high calcium intake potentiates the positive effect of estrogen on bone mass at all skeletal sites and perhaps that of calcitonin on bone mass of the spine...
Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literatureF Cosman
Clinical Research Regional Bone Centers, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
Thromb Res 116:1-13. 2005..The objectives of this investigation were to compare the effects of these three treatments on hemostasis in a head to head randomized placebo-controlled trial...
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosisR Lindsay
Helen Hayes Hospital, West Havershaw, NY, USA
Osteoporos Int 20:943-8. 2009..In postmenopausal women with osteoporosis, increased duration of teriparatide versus placebo treatment was associated with a progressive decrease in the rates of nonvertebral fragility fractures and back pain...
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysisM Parisien
Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw
J Bone Miner Res 7:913-9. 1992..The data further support the hypothesis that in PHPT cancellous bone architecture is maintained...
Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panelP D Miller
Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO 80227, USA
J Clin Densitom 2:323-42. 1999..We will describe, in practical terms, how bone markers can be appropriately incorporated into clinical practice today...
Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in miceAkiko Iida-Klein
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Bone Miner Res 21:274-82. 2006..The study supports further exploration of cyclic PTH regimens for the treatment of osteoporosis...
Daily and cyclic parathyroid hormone in women receiving alendronateFelicia Cosman
Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
N Engl J Med 353:566-75. 2005....
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J miceSara Johnston
Helen Hayes Hospital, Regional Bone Center, 51 North Route 9W, West Haverstraw, New York 10993, USA
Endocrinology 148:4466-74. 2007....
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronateFelicia Cosman
Clinical Research Center, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Bone Miner Res 24:1110-5. 2009..Retreatment with teriparatide may be a viable option for some patients with severe osteoporosis who have received prior teriparatide therapy...
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activityAkiko Iida-Klein
Helen Hayes Hospital, Regional Bone Center, West Haverstraw, NY 10993, USA
Bone 40:391-8. 2007..A cyclic PTH regimen was as effective as a daily regimen in improving cancellous and cortical bone microarchitecture and cellular activity in the murine vertebra...
Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblastsDavid W Dempster
Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw, New York 10993, USA
J Cell Biochem 95:139-48. 2005..This suggests a dual regulatory mechanism, whereby PTH acts both directly on osteoclasts and also, indirectly, via osteoblasts...
Therapeutic potential of parathyroid hormoneFelicia Cosman
Regional Bone Center, Helen Hayes Hospital, Route 9W, West Haverstraw, New York, NY 10993, USA
Curr Osteoporos Rep 2:5-11. 2004....
Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivoAkiko Iida-Klein
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
J Clin Densitom 6:25-33. 2003..We conclude that in vivo DXA BMD measurements in mice are very reliable with high precision and acceptable accuracy, and therefore useful for longitudinal studies of the mouse skeleton...
Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in miceH Zhou
Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw, NY 10993-1195, USA
Bone 32:513-20. 2003..Our results also support an interaction between PTH anabolic action and mechanical loading...
One year outcomes and costs following a vertebral fractureR Lindsay
Helen Hayes Hospital, West Haverstraw, NY, USA
Osteoporos Int 16:78-85. 2005..These results suggest that therapies with proven, rapid efficacy may offer important economic value to healthcare payers, providers and patients...
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerationsAnna N A Tosteson
Department of Medicine, Dartmouth Medical School, and The Dartmouth Institute of Health Policy and Clinical Practice ANAT, Lebanon, NH 03756, USA
Am J Manag Care 14:605-15. 2008..To evaluate the cost-effectiveness of osteoporosis treatments for women at high fracture risk and estimate the population-level impact of providing bisphosphonate therapy to all eligible high-risk US women...
Skeletal effects of vitamin d supplementation in postmenopausal black womenJ W Nieves
Clinical Research and Regional Bone Centres, Helen Hayes Hospital, Route 9W, West Haverstraw, NY, 10993, USA
Calcif Tissue Int 91:316-24. 2012..Vitamin D supplementation does not appear to influence bone loss in black women. However, in the FF polymorphism of the VDR gene group, vitamin D supplementation may retard the higher rate of bone loss...
Alternative strategies for prevention of postmenopausal osteoporosisR Lindsay
Columbia University, New York, NY
Public Health Rep 104:66-70. 1989..This review will deal primarily with the decision to introduce estrogen treatment, and the efficacy of estrogens,as well as alternative forms of prevention...
The anabolic effects of parathyroid hormoneM R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Osteoporos Int 13:267-77. 2002
Vitamin D economy in blacksFelicia Cosman
Regional Bone Center and Clinical Research Centers, Helen Hayes Hospital, West Haverstraw, New York, USA
J Bone Miner Res 22:V34-8. 2007..Benefits of vitamin D supplements in blacks may still play a role, however, in the prevention of other chronic diseases...
Males have larger skeletal size and bone mass than females, despite comparable body sizeJeri W Nieves
Clinical Research and Regional Bone Centers, Helen Hayes Hospital, West Haverstraw, New York 10993, USA
J Bone Miner Res 20:529-35. 2005..Despite comparable body size, males have greater BMC and BMD at the hip and distal tibia and greater tibial cortical thickness. This may confer greater skeletal integrity in males...
The effects of hormone replacement on the biomechanical properties of the uterosacral and round ligaments in the monkey modelMichael D Vardy
Columbia College of Physicians and Surgeons, New York, NY, USA
Am J Obstet Gynecol 192:1741-51. 2005....
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trialsHugh Taggart
Department of Health Care for the Elderly, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
Mayo Clin Proc 77:262-70. 2002..The results of this extensive evaluation indicate that daily treatment with 5 mg of risedronate sodium is not associated with an increased frequency of adverse GI tract effects, even among patients at high risk for these events...
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trialIan H Thorneycroft
Department of Obstetrics and Gynecology, University of South Alabama, Mobile, AL, USA
Am J Obstet Gynecol 197:137.e1-7. 2007..The objective of the study was to determine the effects of several doses of conjugated estrogens (CE) and CE plus medroxyprogesterone acetate (MPA) on body composition (BC)...
Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatmentBarbara M Misof
Ludwig Boltzmann Institute of Osteology and Fourth Medical Department, Hanusch Hospital and UKH Meidling, A-1140 Vienna, Austria
J Clin Endocrinol Metab 88:1150-6. 2003..The findings confirm the observations that PTH stimulates skeletal remodeling, resulting in an increased percentage of newly formed bone matrix of lower mineral density...
Calcium and fracture riskJeri W Nieves
Am J Clin Nutr 86:1579-80. 2007
What have we learned from clinical studies? Fractures and the interactions of bone mass and remodelingRobert Lindsay
Osteoporos Int 14:S8-11. 2003..Here we attempt to assemble the knowledge that we currently have about the mechanisms involved in fracture events...
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatmentRichard Prince
Department of Endocrinology and Diabetes and University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
J Bone Miner Res 20:1507-13. 2005..CONCLUSIONS: While the study design is observational, the results support a sustained effect of teriparatide in reducing the risk of nonvertebral fragility fractures up to 30 months after discontinuation of treatment...
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture riskNelson B Watts
University of Cincinnati Osteoporosis Center, Cincinnati, OH, USA
J Clin Densitom 7:255-61. 2004..Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk...
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosisAnthony B Hodsman
Department of Medicine, Lawson Health Research Institute, University of Western Ontario, London, Ontario, Canada N6A 4V2
J Clin Endocrinol Metab 88:5212-20. 2003..Dose-related incidences of transient hypercalcemia occurred, but only one patient (100-microg group) was withdrawn because of repeated hypercalcemia. Thus, full-length PTH was efficacious and safe over 12 months...
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialSusan L Greenspan
University of Pittsburgh, Osteoporosis Prevention and Treatment Center, Pittsburgh, Pennsylvania 15213, USA
Ann Intern Med 146:326-39. 2007..Recombinant human parathyroid hormone (1-84) (PTH) increases bone mass and strength and improves bone quality by stimulating new bone formation...
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityKenneth Saag
University of Alabama School of Medicine, 1530 3rd Avenue South, FOT 820D, Birmingham, AL 35294 3408, USA
Bone 40:1238-43. 2007..v. infusion of ZOL 5 mg reduced urine NTX levels more rapidly than weekly oral ALN 70 mg. The majority of study patients preferred an i.v. treatment regimen of ZOL 5 mg over weekly osteoporosis therapy with ALN 70 mg...
Short-term urogenital effects of raloxifene, tamoxifen, and estrogenMichael D Vardy
Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, USA
Am J Obstet Gynecol 189:81-8. 2003..The purpose of this study was to assess the urogenital effects of raloxifene, tamoxifen, conjugated equine estrogen, and placebo in healthy postmenopausal women...
Relation of lower-extremity amputation to all-cause and cardiovascular disease mortality in American Indians: the Strong Heart StudyHelaine E Resnick
Department of Epidemiology and Statistics, MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783
Diabetes Care 27:1286-93. 2004..To compare risk of all-cause and cardiovascular disease (CVD) mortality in people with a lower-extremity amputation (LEA) attributable to diabetes and people without an LEA...
Health professional's guide to rehabilitation of the patient with osteoporosisFrancis J Bonner
Medical Director, Rehabilitation Hospital of South Jersey, Vineland, NJ, USA
Osteoporos Int 14:S1-22. 2003
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronateNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219, USA
Osteoporos Int 14:437-41. 2003..The use of appropriate historical control data provides an approach to the assessment of fracture effects in osteoporosis trials for which placebo-controlled data are not available...
Research Grants
- A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTHRobert Lindsay; Fiscal Year: 2009..abstract_text> ..
- 6th International Symposium on OsteoporosisRobert Lindsay; Fiscal Year: 2005..abstract_text> ..
- Cyclic Versus Daily Teriparatide on Bone Mass, Microstructure and StrengthRobert Lindsay; Fiscal Year: 2010..We believe that the periods where no TPTD is given in the cyclic regimen will allow for ongoing recovery of the supply of osteoblasts and will ultimately results in greater gains in bone mass and strength. ..
